Jefferies upgraded Chemed (CHE) to Buy from Hold with a price target of $550, up from $490. The company’s fiscal 2026 reimbursement, particularly in Florida, came in more favorable than expected, the analyst tells investors in a research note. The firm believes this positions Chemed for 2026 EBITDA at the high end of the current Street range. Better than expected reimbursement and “aggressive” share buybacks should drive the stock’s multiple higher in the near-term, contends Jefferies.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHE:
- Optimistic Outlook for Chemed: Buy Rating Supported by Favorable Medicare Rates and Strategic Share Repurchases
- Chemed board authorizes additional $300M for stock repurchases
- Chemed board declares increased quarterly dividend of 60c per share
- Chemed price target lowered to $580 from $650 at Oppenheimer
- Chemed’s Earnings Call: Challenges and Growth